Adam Hawkridge, Ph.D. leads the glycoproteomics laboratory, which focuses on developing innovative approaches in quantitative mass spectrometry-based proteomics. The lab uses these approaches to investigate protein interactions, disease treatments, and regiospecific glycoproteomics mapping of tissues. The laboratory is highly collaborative, and members are expected to develop strong analytical skills to solve important biomedical problems.
Hawkridge's laboratory group focuses on mass spectrometry-based proteomics technology development at the interface of bioanalytical chemistry and clinical translational. They work in close collaboration with basic researchers and clinicians to address diseases of the lung (cystic fibrosis, COPD, NSCLC) and bone marrow (hematopoiesis) while continuing to contribute to technology development (e.g., method development, gas-phase sequencing of complex carbohydrates, data analysis). Current projects include:
Chemoproteomics methods for discovering investigational drug targets and complex carbohydrate-protein interactions
Quantitative glycoproteomics workflow development (i.e., TMT-labeling, off-line UHPLC fractionation, MS/MS method, and data analysis) for comparative analysis of hematopoietic tissues and cells
Gas-phase MS/MS sequencing strategy development for improving glycosaminoglycan structural analysis
Members of the lab develop broad bioanalytical skills in biological sample handling and preparation (e.g., tissues, cells, recombinant proteins), separation science, tandem mass spectrometry, and data analysis in the context of translational research projects
Ph.D. (Chemistry), University at Buffalo, 2000
B.S. (Chemistry), Virginia Tech, 1996
Postgraduate Training
Post Doctoral Fellow (Mayo Clinic, Mayo Proteomics Research Center), 2003-2005
Post Doctoral Fellow (University of Arizona, Department of Chemistry & Biochemistry), 2000-2003
